09412nam 22004093 450 991087218190332120240711080259.09783031588150(electronic bk.)9783031588143(MiAaPQ)EBC31522049(Au-PeEL)EBL31522049(CKB)32704648800041(EXLCZ)993270464880004120240711d2024 uy 0engurcnu||||||||txtrdacontentcrdamediacrrdacarrierClinical Trials in Optic Nerve Disease Treatment1st ed.Cham :Springer,2024.©2024.1 online resource (337 pages)Print version: Weiss, Jeffrey N. Clinical Trials in Optic Nerve Disease Treatment Cham : Springer,c2024 9783031588143 Intro -- Preface -- Contents -- Chapter 1: Introduction to Optic Nerve Disease -- Further Reading -- Chapter 2: Stem Cell Studies in Optic Nerve Disease Treatment -- Recruiting -- United States -- Stem Cell Ophthalmology Treatment Study II (SCOTS2) -- ClinicalTrials.gov ID NCT03011541 -- Recruiting -- Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases -- ClinicalTrials.gov ID NCT00716066 -- Recruiting -- Neurologic Stem Cell Treatment Study (NEST) -- ClinicalTrials.gov ID NCT02795052 -- Recruiting -- Caribbean/South America -- Safety of Cultured Allogeneic Adult Umbilical Cord-Derived Mesenchymal Stem Cells for Eye Diseases -- ClinicalTrials.gov ID NCT05147701 -- Completed -- United States -- Hematopoietic Stem Cell Transplant in Devic's Disease -- ClinicalTrials.gov ID NCT00787722 -- Completed -- China -- Autologous Mesenchymal Stem Cells for the Treatment of Neuromyelitis Optica Spectrum Disorders -- ClinicalTrials.gov ID NCT02249676 -- Completed -- Turkey -- Therapy of Toxic Optic Neuropathy Via Combination of Stem Cells with Electromagnetic Stimulation (Magnovision) -- ClinicalTrials.gov ID NCT04877067 -- Completed -- United Kingdom -- Mesenchymal Stem Cells in Multiple Sclerosis (MSCIMS) -- ClinicalTrials.gov ID NCT00395200 -- Terminated -- Canada -- Reason: Recruitment Failure -- Autologous Hematopoietic Stem Cell Transplant in Neuromyelitis Optica (SCT-NMO) -- ClinicalTrials.gov ID NCT01339455 -- Withdrawn -- United States -- Reason: Discontinued by Investigator -- Autologous Transplant to End NMO Spectrum Disorder (ATTEND) -- ClinicalTrials.gov ID NCT03829566 -- Unknown Status -- China -- Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients with Progressive Multiple Sclerosis and Neuromyelitis Optica -- ClinicalTrials.gov ID NCT01364246 -- Unknown Status -- India.Study the Safety and Efficacy of Bone Marrow-Derived Autologous Cells for the Treatment of Optic Nerve Disease (OND) -- ClinicalTrials.gov ID NCT01834079 -- Unknown Status -- Jordan -- Treatment of Optic Neuropathies Using Autologous Bone Marrow-Derived Stem Cells -- ClinicalTrials.gov ID NCT02638714 -- Unknown Status -- Russian Federation -- Effectiveness and Safety of Adipose-Derived Regenerative Cells for Treatment of Glaucomatous Neurodegeneration -- ClinicalTrials.gov ID NCT02144103 -- Unknown Status -- Spain -- Safety Assessment of Intravitreal Mesenchymal Stem Cells for Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NEUROSTEM) -- ClinicalTrials.gov ID NCT03173638 -- Chapter 3: Gene Therapy Studies in Optic Nerve Disease Treatment -- Recruiting -- China -- Gene Therapy Clinical Trial for the Treatment of Leber's Hereditary Optic Neuropathy (GOLD) -- ClinicalTrials.gov ID NCT04912843 -- Recruiting -- Gene Therapy Clinical Trial for the Treatment of Leber's Hereditary Optic Neuropathy Associated with ND1 Mutations -- ClinicalTrials.gov ID NCT05820152 -- Completed -- United States/Europe -- RESCUE and REVERSE Long-Term Follow-Up (RESTORE) -- ClinicalTrials.gov ID NCT03406104 -- Completed -- Efficacy Study of GS010 for Treatment of Vision Loss from 7 Months to 1 Year from Onset in LHON Due to the ND4 Mutation (REVERSE) (REVERSE) -- ClinicalTrials.gov ID NCT02652780 -- Completed -- Efficacy Study of GS010 for the Treatment of Vision Loss up to 6 Months from Onset in LHON Due to the ND4 Mutation (RESCUE) -- ClinicalTrials.gov ID NCT02652767 -- Completed -- China -- Safety and Efficacy Study of rAAV2-ND4 Treatment of Leber Hereditary Optic Neuropathy (LHON) (rAAV2-ND4) -- ClinicalTrials.gov ID NCT01267422 -- Completed -- France -- Safety Evaluation of Gene Therapy in Leber Hereditary Optic Neuropathy (LHON) Patients.ClinicalTrials.gov ID NCT02064569 -- Not Yet Recruiting -- No Location -- Gene Therapy Clinical Trial for the Treatment of Leber's Hereditary Optic Neuropathy Associated with ND4 Mutations -- ClinicalTrials.gov ID NCT05293626 -- Active, Not Recruiting -- United States/Europe -- Safety Study of an Adeno-Associated Virus Vector for Gene Therapy of Leber's Hereditary Optic Neuropathy (LHON) -- ClinicalTrials.gov ID NCT02161380 -- Active, Not Recruiting -- Efficacy &amp -- Safety Study of Bilateral IVT Injection of GS010 in LHON Subjects Due to the ND4 Mutation for up to 1 Year (REFLECT) -- ClinicalTrials.gov ID NCT03293524 -- Active, Not Recruiting -- China -- A Single Intravitreal Injection of rAAV2-ND4 for the Treatment of Leber's Hereditary Optic Neuropathy -- ClinicalTrials.gov ID NCT03153293 -- Unknown Status -- China -- Efficacy Study of Gene Therapy for the Treatment of Acute LHON Onset Within Three Months (LHON) -- ClinicalTrials.gov ID NCT03428178 -- Chapter 4: Other Treatment Studies for Optic Nerve Disease -- Recruiting -- United States -- Electrical Stimulation for the Treatment of Optic Neuropathies (rtACS) -- ClinicalTrials.gov ID NCT05626426 -- Recruiting -- China -- Targeted Shortwave Diathermy Combined with Perceptual Training for Patients with Severe Traumatic Optic Neuropathy -- ClinicalTrials.gov ID NCT05140486 -- Completed -- United States -- Vision Restoration Therapy (VRT) to Treat Non-arteritic Anterior Ischemic OpticNeuropathy -- ClinicalTrials.gov ID NCT00140491 -- Completed -- A New Medicine to Treat Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) (Ampyra) -- ClinicalTrials.gov ID NCT01975324 -- Completed -- Ranibizumab Therapy for Non-arteritic Ischemic Optic Neuropathy (NAION) -- ClinicalTrials.gov ID NCT00561834 -- Completed.A Study Investigating the Safety, Tolerability, and Efficacy of Elamipretide Topical Ophthalmic Solution for Treatment of Leber's Hereditary Optic Neuropathy -- ClinicalTrials.gov ID NCT02693119 -- Completed -- Study to Assess the Efficacy and Safety of Raxone in LHON Patients (LEROS) -- ClinicalTrials.gov ID NCT02774005 -- Completed -- Lipoic Acid as a Treatment for Acute Optic Neuritis -- ClinicalTrials.gov ID NCT01294176 -- Completed -- Single Oral Doses Study of Nerispirdine on Visual Function in Patients with Multiple Sclerosis -- ClinicalTrials.gov ID NCT00772525 -- Completed -- Intravenous Immunoglobulin Therapy in Optic Neuritis -- ClinicalTrials.gov ID NCT00000117 -- Completed -- A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic's Disease) -- ClinicalTrials.gov ID NCT00304291 -- Completed -- Efficacy and Safety Study of Satralizumab (SA237) as Add-On Therapy to Treat Participants with Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD) -- ClinicalTrials.gov ID NCT02028884 -- Completed -- Ampyra for Optic Neuritis in Multiple Sclerosis -- ClinicalTrials.gov ID NCT01337986 -- Completed -- Efficacy and Safety Study of Satralizumab (SA237) as Monotherapy to Treat Participants with Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD) -- ClinicalTrials.gov ID NCT02073279 -- Completed -- Europe -- Paraorbital-Occipital Alternating Current Stimulation Therapy for Optic Neuropathy (MCT optnerve) -- ClinicalTrials.gov ID NCT01280877 -- Completed -- Trial of Alternating Current Stimulation in Optic Neuropathy (SCT Optnerve) -- ClinicalTrials.gov ID NCT01270126 -- Completed -- Citicoline in Non-arteritic Ischemic Optic Neuropathy -- ClinicalTrials.gov ID NCT03758118 -- Completed -- Middle East -- Traumatic Optic Neuropathy Treatment Trial 2 (TONTT-2).ClinicalTrials.gov ID NCT03308448 -- Terminated -- United States -- Near-Infrared Light-Emitting Diode (NIR-LED) Therapy for Leber's -- Hereditary Opticneuropathy (LHON) (LHON) -- ClinicalTrials.gov ID NCT01389817 -- Unknown Status -- Middle East -- NAION Treatment with Oral Prednisolone and Erythropoietin Injection (NAION) -- ClinicalTrials.gov ID NCT03715881 -- Unknown Status -- Spain -- Intravenous Infusion of Prostaglandins as Therapy in Patients with Anterior Non-arteritic Ischemic Optic Neuropathy (PG-NAION) -- ClinicalTrials.gov ID NCT03851562 -- Chapter 5: Addendum: Hereditary Optic Neuropathies -- Leber's Hereditary Optic Neuropathy -- Nonarteritic Ischemic Optic Neuropathy (NAION) -- Neuromyelitis Optica (NMO, Devic's Disease) -- Index.Weiss Jeffrey N927848MiAaPQMiAaPQMiAaPQ9910872181903321Clinical Trials in Optic Nerve Disease Treatment4174465UNINA